

Scientist Profile

1. **Name of the Scientist:** Dr. Amit Kumar Singh
2. **Designation:** Scientist-E & In-Charge
3. **Division:** Experimental Animal Facility Division
4. **Official Email address:** amits.hq@icmr.gov.in
5. **Qualifications:** M.V.Sc., Ph.D
6. **Research interests:** Tuberculosis & Leprosy (Pre-clinical studies, Host-directed therapeutics, Mycobacteriophage-based therapeutics)
7. **Research experience (in Years):** >12 years
8. **H-index:** 17
9. **Total number of Publications:** 52
https://scholar.google.com/citations?hl=en&user=uE-KhEIAAAAJ&sortby=pubdate&view_op=list_works&gmla=AETOMgH_eLEllf5zmkVz15YjYm1JNbVACWaRHBGCf7WAzQXCU7tFZ0q51VCldz2MLqscOOywlIrox0iYVdzc1s2d
10. **Patents (Filed/ Awarded):** Nil
11. **List of research grants received (Reverse chronological order):**

S. No.	Title	Funding Agency	Period
1	Restoring adaptive immunity of foamy macrophages against Mycobacterium tuberculosis infection by Sphingosine -1 Phosphate in experimental model system	ICMR (5/8/5/46/Adhoc/2022/ECD-I)	14.10.2023- 13.10.2026
2	Evaluation of anti-tubercular, safety and immunomodulatory activities of Unani pharmacopeial formulations (UPF) Qurs-e-Tabasheer Sartani and Arqe-Hara Bhara through in-vitro and in-vivo studies	Central Council for Research in Unani Medicine (3-11/2021-CCRUM/Tech)	31.07.2023- 30.07.2025

3	Investigating Therapeutic Impact of L-Serine Derived Sphingolipids for Controlling <i>Mycobacterium tuberculosis</i> Infection in Host	DHR (R.11013/06/2021-GIA/HR)	14.01.2022- 13.01.2025
4	N2B (Nose-to-Brain) delivery of anti-TB drugs using particulate drug delivery system to ameliorate Tuberculous Meningitis (TBM) and enhance functional recovery	ICMR 5/8/5/68/Adhoc/2020/ECD-I)	1.03.2021- 28.02.2024
5	An investigational study on Mycobacteriophages and their enzymes as new drugs (IND) for treating tuberculosis	ICMR (File No: 5/8/5/38/2019- ECD-I)	25.10.2019- 24.04.2023
6	Validation of herbal healers claims for tuberculosis	National Innovation foundation, Gujarat (File No.: NIF/VARD/11205)	01.04.2018- 30.03.2021
7	Evaluation of enriched fractions of lead plant extracts for <i>in-vivo</i> anti-tuberculosis and immunomodulatory potentials with first line anti-TB drugs for the development of adjunct phytotherapy	ICMR (F. No. 65/9/2020/PD/BMS)	15.02.2021- 14.02.2023
8	Development of mice models for amyloidosis: A rare disease	ICMR	1.12.2019- 30.06.2023
9	Bioprocess development and Preclinical evaluation of novel anti TB antibiotic, Transitmycin isolated from marine <i>Streptomyces</i> sp. MTCC 5597	ICMR (File No.: 5/8/5/8/TF/2017/ECD-I)	14.02.2019- 30.04.2020

12. Awards/ Recognitions/Honors:

S. No	Award Details	Awarded by	Year
1	ICMR-DHR International Fellowship for Young Biomedical Scientists (Long term)	ICMR, New Delhi, India	2024
2	Travel Fellowship to attend 12 th International Meeting on 'Human Genome Variation and Complex Genome Analysis (HGV2011)' at Berkeley, California, USA	Human Genome Variation Society, USA	2011
3	International Travel Grant for Young Scientists to attend a <i>Keystone Symposium</i> on 'Tuberculosis: Immunology, Cell Biology and Novel Vaccination Strategies (J3)' at Vancouver, Canada	Department of Science & Technology (DST), New Delhi, India	2011

13. Academic activities (Last five years)

Member of scientific societies/ bodies / committees: 2 (1. LASA, India, (Life time member) 2.

Indian Association of Leprologists (Life time Member))

- Conference/ Webinar/ Workshop/ Training organized- Nil
- No. of Conference/ Webinar/ Workshop/ Training attended- >20
- No. of invited lectures delivered: >5
- No of students supervised: (Ph.D....., MD....., M.Tech / M.Sc.....)

PhD: 2 as Co-Co-supervisor

M.Sc.: 18

